Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 28 DAY versus CONEXXENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 28 DAY versus CONEXXENCE.
BREVICON 28-DAY vs CONEXXENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
None Documented
None Documented
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Renal: 70% unchanged; fecal: 30% (including metabolites).
Category C
Category C
Oral Contraceptive
Oral Contraceptive